Evidence map›Paper›PMID 26401088›Full record

ArticleWorld journal of gastroenterology2015

Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand.

Jane Vermunt, Margaret Fraser, Peter Herbison, Anna Wiles, Martin Schlup, Michael Schultz

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jane VermuntJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Margaret FraserJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Peter HerbisonJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Anna WilesJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Martin SchlupJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Michael SchultzJane Vermunt, Anna Wiles, Martin Schlup, Michael Schultz, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
University of Otago · NZDunedin Public Hospital · NZSouthern District Health Board · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine the prevalence of infection with hepatitis C virus (HCV) in those most at risk of advanced liver disease and to identify gaps in knowledge of HCV.

methodsQuestionnaires were mailed to randomly selected residents aged 40-59 to assess the extent of their general knowledge about HCV. The questionnaire assessed demographics, the extent of general knowledge about viral hepatitis, potential risks for infection and the prevalence of risk factors associated with increased progression of liver fibrosis. Anonymised residual laboratory blood samples from 40-59 years old people from Dunedin taken in hospital or in the community, were tested for HCV antibodies and alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT). Linear regression was performed to examine whether the demographics sex, age, socio-economic status, qualification level and occupation sector (categorical variables) were predictors of level of general knowledge about hepatitis. For the demographics that were found to be significant predictors of score outcome, multiple regression analysis was used to determine independent effects. χ (2) tests were used to compare our selected sample and our responder population demographics, to the demographics of the entire 40-59 years old population in Dunedin using the 2006 NZ census data. Exact confidence intervals for the proportion positive for HCV and HBV were calculated using the binomial distribution.

resultsThe response rate to the mailed questionnaire was 431/1400 (30.8%). On average 59.4% questions were answered correctly. Predictors for higher scores, indicating greater knowledge about symptoms and transmission included sex (female, P < 0.01), higher level of qualification (P < 0.000) and occupation sector (P < 0.000). Sharing intravenous drug utensils was a known risk factor for disease transmission (94.4%), but the sharing of common household items such as a toothbrush was not. 93% of the population were unaware that HCV infection can be asymptomatic. 25% did not know that treatment was available in New Zealand and of those who did know, only 40% assumed it was funded. Six hundred and eighty-two residual anonymised blood samples were tested for HCV antibodies, ALT, AST and GGT. The prevalence for HCV was 4.01%, 95%CI: 2.6%-5.8%. Liver function tests were not useful for identifying likelyhood of HCV infection.

conclusionPrevalence of HCV in our population is high, and the majority have limited knowledge of HCV and its treatment.

Indexed as

Health Knowledge, Attitudes, PracticeAdultAlanine TransaminaseAntiviral AgentsAspartate AminotransferasesBiomarkersChi-Square DistributionFemalegamma-GlutamyltransferaseHepatitis AntibodiesHepatitis CHumansLinear ModelsMaleMiddle AgedNew ZealandAlanine TransaminaseAntiviral AgentsAspartate AminotransferasesBiomarkersgamma-Glutamyltransferasegamma-glutamyltransferase, humanHepatitis AntibodiesDirect acting antiviral agentsHepatitis CInfectionKnowledgeNew ZealandPrevalenceTransmissionTreatment

Identifiers

PMID26401088
PMCPMC4572804
OpenAlexW2417376558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.